ReviewCancers2021
Quantitative FDG PET Assessment for Oncology Therapy.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value ofFrontiers in immunology · 2022Pooled it
- Association ofMolecular imaging and radionuclide therapy · 2026Article
- FDG-PET/CT-based treatment response predicts recurrence and overall survival in locally advanced cervical cancer.BMC medical imaging · 2026Article
- Optimization of a Q.Clear PET image reconstruction based on bayesian optimization in oncology and neurology applications.Physical and engineering sciences in medicine · 2026Article
- Diagnostic performance ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Integrating Multiparametric MRI and PSMA PET Imaging in Prostate Cancer: Toward a Unified Diagnostic and Risk-Stratification Paradigm.Medicina (Kaunas, Lithuania) · 2026Review
- Harmonisation of standard uptake values in long-axial field-of-view PET/CT: an exploratory study.EJNMMI physics · 2026Article
- Molecular Imaging in Gastric Cancer: [¹⁸F]FDG and Fibroblast Activation Protein-Targeted PET/CT.Journal of gastric cancer · 2026Review
- Article
- Selegiline, a monoamine oxidase-B inhibitor as a modulator of metabolic reprogramming for cancer therapy: a review.Frontiers in pharmacology · 2026Review
- Diagnostic Imaging of the Skeletal System: Overview of Applications in Human and Veterinary Medicine.Bioengineering (Basel, Switzerland) · 2025Review
- QuantitativeEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies.World journal of clinical oncology · 2025Review
- The diagnostic value of the multiparameter combination diagnostic model based on 2-[Quantitative imaging in medicine and surgery · 2025Article
- Methodology Development for Investigating Pathophysiological [Biomedicines · 2025Article
- PET-Assessed Metabolic Tumor Volume Across the Spectrum of Solid-Organ Malignancies: A Review of the Literature.Biomedicines · 2025Review
- Predicting response and survival to first-line treatment with baseline [Therapeutic advances in medical oncology · 2025Article
- Enhancing prognostication and treatment response evaluation in primary CNS lymphoma with 18F-FDG-PET/CT.Neuro-oncology · 2024Article
- Pre-Hydration and a Forced Diuresis Protocol forJournal of clinical medicine · 2024Article
- The impact of introducing deep learning based [EJNMMI research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Positron emission tomography (PET) has unique characteristics for quantitative assessment of tumour biology in vivo. Accumulation of F-18 fluorodeoxyglucose (FDG) may reflect tumour characteristics based on its metabolic activity. Quantitative assessment of FDG uptake can often be applied for treatment monitoring after chemotherapy or chemoradiotherapy. Numerous studies indicated biochemical change assessed by FDG PET as a more sensitive marker than morphological change estimated by CT or MRI. In addition, those with complete metabolic response after therapy may show better disease-free survival and overall survival than those with other responses. Assessment of metabolic change may be performed using absolute FDG uptake in the tumour (standardized uptake value: SUV). In addition, volumetric parameters such as metabolic tumour volume (MTV) have been introduced for quantitative assessment of FDG uptake in tumour. More recently, radiomics approaches that focus on image-based precision medicine have been applied to FDG PET, as well as other radiological imaging. Among these, texture analysis extracts intratumoral heterogeneity on a voxel-by-voxel basis. Combined with various machine learning techniques, these new quantitative parameters hold a promise for assessing tissue characterization and predicting treatment effect, and could also be used for future prognosis of various tumours, although multicentre clinical trials are needed before application in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.